Search

Search Constraints

You searched for: Author/Creator Louvet, C.

Search Results

1. %TTD and %TUDD: New SAS macro programs to calculate the survival data of the time to deterioration for patient-reported outcomes data in oncology. (February 2022)

2. 2355 Nab-paclitaxel plus gemcitabine or plus simplified LV5FU2 as first- line therapy in patients with metastatic pancreatic adenocarcinoma. A GERCOR randomized phase II study (AFUGEM). (September 2015)

3. 2376 Impact of the definition of time to event endpoint on randomized clinical trials results in oncology (datecan-2): an analysis of 9 pancreatic cancer trials. (September 2015)

5. Autologous Dendritic Cells Prolong Allograft Survival Through Tmem176b‐Dependent Antigen Cross‐Presentation. Issue 5 (14th April 2014)

6. Autologous Dendritic Cells Prolong Allograft Survival Through Tmem176b‐Dependent Antigen Cross‐Presentation. Issue 5 (14th April 2014)

8. Erratum to 'Oxaliplatin, 5-Fluorouracil and Nab-paclitaxel as perioperative regimen in patients with resectable gastric adenocarcinoma: A GERCOR phase II study (FOXAGAST)' [Eur J Cancer 107 (January 2019) 46–52]. (September 2019)

9. Impact of circulating biomarkers in patients with metastatic colorectal cancer treated with first-line FOLFOX-aflibercept therapy. Results of the GERCOR VELVET Phase II study. (December 2016)